This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://localhost/temp/predkladatel/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/resource/domain/vavai/subjekt/
n12http://linked.opendata.cz/ontology/domain/vavai/
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F13%3A00070496%21RIV14-MSM-14110___/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F13%3A00070496%21RIV14-MSM-14110___
rdf:type
n12:Vysledek skos:Concept
dcterms:description
In a group of 233 patients with advanced non-squamous NSCLC who were treated with pemetrexed in first line and in combination with cisplatin, the therapy was well tolerated: termination of treatment due to adverse events was reported only in 3.8% of patients. Median overall was 11.6 months, median progression-free survival was 4.2 months. In a group of 233 patients with advanced non-squamous NSCLC who were treated with pemetrexed in first line and in combination with cisplatin, the therapy was well tolerated: termination of treatment due to adverse events was reported only in 3.8% of patients. Median overall was 11.6 months, median progression-free survival was 4.2 months.
dcterms:title
Pemetrexed in combination with cisplatin in the first-line treatment of non-squamous NSCLC: Czech experience with 233 patients Pemetrexed in combination with cisplatin in the first-line treatment of non-squamous NSCLC: Czech experience with 233 patients
skos:prefLabel
Pemetrexed in combination with cisplatin in the first-line treatment of non-squamous NSCLC: Czech experience with 233 patients Pemetrexed in combination with cisplatin in the first-line treatment of non-squamous NSCLC: Czech experience with 233 patients
skos:notation
RIV/00216224:14110/13:00070496!RIV14-MSM-14110___
n12:predkladatel
n13:orjk%3A14110
n4:aktivita
n16:I
n4:aktivity
I
n4:dodaniDat
n11:2014
n4:domaciTvurceVysledku
n5:2428245 n5:6630197 n5:9067094 n5:9447393
n4:druhVysledku
n17:O
n4:duvernostUdaju
n15:S
n4:entitaPredkladatele
n8:predkladatel
n4:idSjednocenehoVysledku
95674
n4:idVysledku
RIV/00216224:14110/13:00070496
n4:jazykVysledku
n10:eng
n4:klicovaSlova
first-line treatment; NSCLC
n4:klicoveSlovo
n6:NSCLC n6:first-line%20treatment
n4:kontrolniKodProRIV
[76591EA87601]
n4:obor
n9:FC
n4:pocetDomacichTvurcuVysledku
4
n4:pocetTvurcuVysledku
17
n4:rokUplatneniVysledku
n11:2013
n4:tvurceVysledku
Roubec, Jaromír Hejduk, Karel Pešek, Miloš Povolná, Zdenka Zemanová, Milada Kolek, Vítězslav Koubková, Leona Havel, Libor Skřičková, Jana Šatánková, Monika Salajka, František Hrnciarik, Michal Čoupková, Helena Tomíšková, Marcela Bortlíček, Zbyněk Černovská, Markéta Sixtová, Dimka
n14:organizacniJednotka
14110